|
EP0460709B1
(en)
|
1985-01-28 |
1997-05-21 |
Xoma Corporation |
AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
|
|
US5202238A
(en)
|
1987-10-27 |
1993-04-13 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US6004781A
(en)
|
1988-01-22 |
1999-12-21 |
The General Hospital Corporation |
Nucleic acid encoding Ig-CD4 fusion proteins
|
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US5216132A
(en)
|
1990-01-12 |
1993-06-01 |
Protein Design Labs, Inc. |
Soluble t-cell antigen receptor chimeric antigens
|
|
US20020004052A1
(en)
|
1990-05-08 |
2002-01-10 |
David Berd |
Composition comprising a tumor cell extract and method of using the composition
|
|
US5914109A
(en)
|
1990-06-15 |
1999-06-22 |
New York University |
Heterohybridomas producing human monoclonal antibodies to HIV-1
|
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
ATE145428T1
(de)
|
1990-12-14 |
1996-12-15 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
|
US6407221B1
(en)
|
1990-12-14 |
2002-06-18 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US20020111474A1
(en)
|
1990-12-14 |
2002-08-15 |
Capon Daniel J. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US5843728A
(en)
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US5851828A
(en)
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
|
US6753162B1
(en)
|
1991-03-07 |
2004-06-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US5912170A
(en)
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
|
JPH06505396A
(ja)
|
1991-03-08 |
1994-06-23 |
サイトメッド，インコーポレイテッド |
可溶性ｃｄ２８タンパク質およびそれを用いる治療方法
|
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
|
DE69231250T2
(de)
|
1991-10-21 |
2001-03-15 |
Cell Genesys, Inc. |
Kombinierte zelluläre und immunsuppressive therapien
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
EP1757695A3
(en)
|
1992-11-05 |
2008-02-27 |
Sloan Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
AU695869B2
(en)
|
1993-04-06 |
1998-08-27 |
Fred Hutchinson Cancer Research Center |
Chimeric cytokine receptors in lymphocytes
|
|
US6051427A
(en)
|
1993-06-11 |
2000-04-18 |
Cell Genesys, Inc. |
Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
|
|
US5834256A
(en)
|
1993-06-11 |
1998-11-10 |
Cell Genesys, Inc. |
Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
|
|
US5525503A
(en)
|
1993-09-28 |
1996-06-11 |
Dana-Farber Cancer Institute, Inc. |
Signal transduction via CD28
|
|
US5935818A
(en)
|
1995-02-24 |
1999-08-10 |
Sloan-Kettering Institute For Cancer Research |
Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
|
|
WO1996026272A1
(en)
|
1995-02-24 |
1996-08-29 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US5798100A
(en)
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
|
US7354587B1
(en)
|
1994-07-06 |
2008-04-08 |
Immunomedics, Inc. |
Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
|
|
US5716614A
(en)
|
1994-08-05 |
1998-02-10 |
Molecular/Structural Biotechnologies, Inc. |
Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
|
|
AU685693B2
(en)
|
1994-11-01 |
1998-01-22 |
Targeted Genetics Corporation |
Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells
|
|
US5837544A
(en)
|
1995-02-02 |
1998-11-17 |
Cell Genesys, Inc. |
Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
US5830755A
(en)
|
1995-03-27 |
1998-11-03 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
T-cell receptors and their use in therapeutic and diagnostic methods
|
|
US6261787B1
(en)
|
1996-06-03 |
2001-07-17 |
Case Western Reserve University |
Bifunctional molecules for delivery of therapeutics
|
|
US5969102A
(en)
|
1997-03-03 |
1999-10-19 |
St. Jude Children's Research Hospital |
Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
|
|
ATE380873T1
(de)
|
1997-06-11 |
2007-12-15 |
Univ New York |
Prenylcystein carboxyl methyl-transferase, dns, welche für selbige kodiert, und ein verfahren zur suche nach hemmstoffen
|
|
US6759243B2
(en)
|
1998-01-20 |
2004-07-06 |
Board Of Trustees Of The University Of Illinois |
High affinity TCR proteins and methods
|
|
US20090011984A1
(en)
|
1998-02-23 |
2009-01-08 |
Seppo Yla-Herttuala |
Biotin-binding receptor molecules
|
|
NZ507886A
(en)
|
1998-05-19 |
2003-05-30 |
Avidex Ltd |
Multivalent T cell receptor complexes
|
|
US6395152B1
(en)
|
1998-07-09 |
2002-05-28 |
Acm Research, Inc. |
Methods and apparatus for electropolishing metal interconnections on semiconductor devices
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
EP1124568B1
(en)
|
1998-10-21 |
2007-08-22 |
Altor BioScience Corporation |
Polyspecific binding molecules and uses thereof
|
|
US7217421B1
(en)
|
1998-11-03 |
2007-05-15 |
Cell Genesys, Inc. |
Cancer-associated antigens and methods of their identification and use
|
|
AU3389700A
(en)
|
1999-03-01 |
2000-09-21 |
Cell Genesys, Inc. |
Anti-neoplastic compositions and uses thereof
|
|
JP2002541845A
(ja)
|
1999-04-16 |
2002-12-10 |
セルテック セラピューティックス リミテッド |
合成膜貫通成分
|
|
US6699972B1
(en)
|
1999-06-25 |
2004-03-02 |
Academia Sinica |
Chimeric protein and method of controlling tumor growth using the protein
|
|
EP1908780B1
(en)
|
2000-01-03 |
2012-08-15 |
The Trustees Of The University Of Pennsylvania |
Novel chimeric proteins and methods for using the same
|
|
US7572891B2
(en)
|
2000-02-14 |
2009-08-11 |
The Regents Of The University Of California |
Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
|
|
US6770749B2
(en)
|
2000-02-22 |
2004-08-03 |
City Of Hope |
P53-specific T cell receptor for adoptive immunotherapy
|
|
DZ3332A1
(fr)
|
2000-03-31 |
2001-10-11 |
Purdue Research Foundation |
Methode de traitement a l'aide de conjugues ligand-immunogene
|
|
AU2001255580A1
(en)
|
2000-04-21 |
2001-12-11 |
Rutgers, The State University Of New Jersey |
Methods and compositions for the diagnosis of schizophrenia
|
|
US6524572B1
(en)
|
2000-06-26 |
2003-02-25 |
Rainbow Therapeutic Company |
Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
|
|
AU2002227498A1
(en)
|
2000-07-31 |
2002-02-13 |
Kyogo Itoh |
Tumor antigen
|
|
US7666424B2
(en)
|
2001-10-17 |
2010-02-23 |
Sloan-Kettering Institute For Cancer Research |
Methods of preparing and using single chain anti-tumor antibodies
|
|
US7446179B2
(en)
|
2000-11-07 |
2008-11-04 |
City Of Hope |
CD19-specific chimeric T cell receptor
|
|
US7723111B2
(en)
|
2001-03-09 |
2010-05-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Activated dual specificity lymphocytes and their methods of use
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
US20030171546A1
(en)
|
2001-04-30 |
2003-09-11 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US7939059B2
(en)
|
2001-12-10 |
2011-05-10 |
California Institute Of Technology |
Method for the generation of antigen-specific lymphocytes
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
WO2004016643A2
(en)
|
2002-08-16 |
2004-02-26 |
Yeda Research And Development Co. Ltd. |
Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
|
|
WO2004021861A2
(en)
|
2002-09-03 |
2004-03-18 |
Vit Lauermann |
Targeted release
|
|
DE10244457A1
(de)
|
2002-09-24 |
2004-04-01 |
Johannes-Gutenberg-Universität Mainz |
Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
|
|
JP2004113062A
(ja)
|
2002-09-25 |
2004-04-15 |
Teruyuki Nagamune |
キメラ受容体を有する動物細胞とその利用
|
|
US7459285B2
(en)
*
|
2002-12-10 |
2008-12-02 |
Echelon Biosciences Incorporated |
Compounds and methods of use thereof for assaying lysophospholipase D activity
|
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
DE602005015687D1
(de)
|
2004-03-02 |
2009-09-10 |
Cellectar Inc |
Phospholipid-analoga für die behandlung von krebs
|
|
ES2678094T3
(es)
|
2004-07-10 |
2018-08-08 |
Fox Chase Cancer Center |
Líneas de células asesinas naturales genéticamente modificadas
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
WO2006036445A2
(en)
|
2004-09-24 |
2006-04-06 |
Trustees Of Dartmouth College |
Chimeric nk receptor and methods for treating cancer
|
|
PT1809321E
(pt)
|
2004-10-08 |
2012-05-17 |
Us Gov Health & Human Serv |
Imunoterapia adotiva com sobrevivência aumentada de linfócitos
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
WO2007044033A2
(en)
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
|
EP1979379B1
(en)
|
2005-12-02 |
2013-09-18 |
Dana-Farber Cancer Institute |
Carbonic anhydrase ix (g250) antibodies and methods of use thereof
|
|
US7919079B2
(en)
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
|
US9334330B2
(en)
|
2006-10-10 |
2016-05-10 |
Universite De Nantes |
Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
|
|
JP2010509570A
(ja)
|
2006-11-03 |
2010-03-25 |
パーデュー・リサーチ・ファウンデーション |
エクスビボフローサイトメトリーの方法および装置
|
|
EP2123754B1
(en)
|
2007-01-30 |
2011-04-06 |
Forerunner Pharma Research Co., Ltd. |
CHIMERIC Fc GAMMA RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR
|
|
PT2126054T
(pt)
|
2007-01-31 |
2016-10-12 |
Yeda Res & Dev |
Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias
|
|
WO2008097926A2
(en)
|
2007-02-02 |
2008-08-14 |
Yale University |
Transient transfection with rna
|
|
US8865169B2
(en)
|
2007-02-20 |
2014-10-21 |
Tufts University |
Methods and systems for multi-antibody therapies
|
|
US8389282B2
(en)
|
2007-03-30 |
2013-03-05 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
CN101820913A
(zh)
|
2007-08-09 |
2010-09-01 |
第一三共株式会社 |
在表达含死亡结构域的受体的细胞中诱导细胞凋亡的免疫脂质体
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
WO2009117117A1
(en)
|
2008-03-19 |
2009-09-24 |
Altor Bioscience Corporation |
T cell receptor fusions and conjugates and methods of use there of
|
|
JP5779090B2
(ja)
|
2008-04-09 |
2015-09-16 |
マックスサイト インコーポレーティッド |
新規に単離された細胞の治療組成物の操作および送達
|
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
CA2735456C
(en)
|
2008-08-26 |
2021-11-16 |
City Of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
JP5675619B2
(ja)
|
2008-09-17 |
2015-02-25 |
エンドサイト, インク.Endocyte, Inc. |
葉酸拮抗薬の葉酸受容体結合性コンジュゲート
|
|
EP2364368B1
(en)
|
2008-11-07 |
2014-01-15 |
Sequenta, Inc. |
Methods of monitoring conditions by sequence analysis
|
|
WO2010059253A2
(en)
|
2008-11-24 |
2010-05-27 |
Massachusets Institute Of Technology |
Methods and compositions for localized agent delivery
|
|
US20110178279A1
(en)
|
2009-08-03 |
2011-07-21 |
Williams John C |
Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
|
|
US8877199B2
(en)
|
2009-05-15 |
2014-11-04 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
B cell surface reactive antibodies
|
|
US20100322909A1
(en)
|
2009-06-17 |
2010-12-23 |
The University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Th1-associated micrornas and their use for tumor immunotherapy
|
|
JP5934099B2
(ja)
|
2009-10-01 |
2016-06-15 |
アメリカ合衆国 |
抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
|
|
US9211321B2
(en)
|
2009-10-27 |
2015-12-15 |
Immunicum Ab |
Method for proliferation of antigen-specific T cells
|
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
JP5956342B2
(ja)
|
2009-11-03 |
2016-07-27 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
|
|
WO2011072088A2
(en)
|
2009-12-08 |
2011-06-16 |
Wilson Wolf Manufacturing Corporation |
Improved methods of cell culture for adoptive cell therapy
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
EP2529020B1
(en)
|
2010-01-28 |
2018-04-25 |
The Children's Hospital of Philadelphia |
A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
|
|
CA2791975C
(en)
|
2010-02-04 |
2021-02-09 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
KR20120117931A
(ko)
|
2010-02-12 |
2012-10-24 |
온코메드 파마슈티칼스, 인크. |
폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
|
|
SA111320200B1
(ar)
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
|
|
WO2011130491A2
(en)
|
2010-04-14 |
2011-10-20 |
Roger Williams Medical Center |
Methods and compositions for treating hiv
|
|
EP2566954B2
(en)
|
2010-05-04 |
2022-11-02 |
Yeda Research and Development Co. Ltd. |
Immunotherapy using redirected allogeneic cells
|
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
|
WO2012012695A2
(en)
|
2010-07-23 |
2012-01-26 |
Fred Hutchinson Cancer Research Center |
A method for the treatment of obesity
|
|
EP3115373B1
(en)
|
2010-09-08 |
2019-08-28 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Chimeric antigen receptors with an optimized hinge region
|
|
WO2012136231A1
(en)
|
2010-09-08 |
2012-10-11 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Interleukin 15 as selectable marker for gene transfer in lymphocytes
|
|
EP2614143B1
(en)
|
2010-09-08 |
2018-11-07 |
Baylor College Of Medicine |
Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
|
|
US9345748B2
(en)
|
2010-09-21 |
2016-05-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-SSX-2 T cell receptors and related materials and methods of use
|
|
JP5719443B2
(ja)
|
2010-09-26 |
2015-05-20 |
ダ・ユー・エンタープライジズ、エルエルシー |
組換え巨大分子製造方法
|
|
US9845362B2
(en)
|
2010-10-08 |
2017-12-19 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
|
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012076059A1
(en)
|
2010-12-09 |
2012-06-14 |
Stichting Het Nederlands Kanker Instituut |
Immune restricted peptides with increased efficacy
|
|
JP5897035B2
(ja)
|
2010-12-14 |
2016-03-30 |
ユニバーシティ オブ メリーランド，ボルチモア |
汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法
|
|
EA201401134A1
(ru)
|
2011-02-11 |
2015-05-29 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
|
|
EP2502934B1
(en)
|
2011-03-24 |
2018-01-17 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
|
|
ES2785081T3
(es)
|
2011-04-01 |
2020-10-05 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
|
|
EP3459560B1
(en)
|
2011-04-08 |
2021-02-24 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
|
US9492529B2
(en)
|
2011-04-13 |
2016-11-15 |
Immunicum Ab |
Method for priming of T cells
|
|
CN103502439B
(zh)
|
2011-04-13 |
2016-10-12 |
因缪尼卡姆股份公司 |
用于抗原特异性t细胞增殖的方法
|
|
US9206257B2
(en)
|
2011-04-19 |
2015-12-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for glypican-3 and use thereof
|
|
GB201108236D0
(en)
|
2011-05-17 |
2011-06-29 |
Ucl Business Plc |
Method
|
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
|
SI2755997T1
(sl)
|
2011-09-15 |
2018-11-30 |
The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health |
T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
|
|
KR20140060541A
(ko)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 rna 조작된 t 세포
|
|
EP3692794A1
(en)
|
2011-09-16 |
2020-08-12 |
Baylor College of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
US9708384B2
(en)
|
2011-09-22 |
2017-07-18 |
The Trustees Of The University Of Pennsylvania |
Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
|
|
JP6053688B2
(ja)
|
2011-10-07 |
2016-12-27 |
国立大学法人三重大学 |
キメラ抗原受容体
|
|
JP6267644B2
(ja)
|
2011-10-20 |
2018-01-24 |
アメリカ合衆国 |
抗ｃｄ２２キメラ抗原受容体
|
|
JP6074435B2
(ja)
|
2011-10-26 |
2017-02-01 |
ナショナル キャンサー センター |
変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物
|
|
WO2013063019A1
(en)
|
2011-10-28 |
2013-05-02 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
|
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
EP2817330B1
(en)
|
2012-02-22 |
2020-07-08 |
The Trustees of the University of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
|
BR112014020502A2
(pt)
|
2012-02-22 |
2019-09-24 |
Univ Pennsylvania |
sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
|
|
CA2868121C
(en)
|
2012-03-23 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
AU2013246443B2
(en)
|
2012-04-11 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
|
CN104395344B
(zh)
|
2012-05-07 |
2019-08-13 |
达特茅斯大学理事会 |
抗b7-h6抗体、融合蛋白及其使用方法
|
|
ES2835200T3
(es)
|
2012-05-22 |
2021-06-22 |
Us Health |
Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
|
|
SG10201806573TA
(en)
|
2012-05-25 |
2018-09-27 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
CN104520331B
(zh)
|
2012-06-01 |
2018-09-07 |
美国政府(由卫生和人类服务部的部长所代表) |
磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
|
|
CA2875451A1
(en)
|
2012-06-08 |
2013-12-12 |
Kinki University |
Antibody against transporter and use thereof
|
|
KR20210149195A
(ko)
|
2012-07-13 |
2021-12-08 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
형질도입된 ｔ 세포의 투여 적합성을 평가하는 방법
|
|
KR20150029714A
(ko)
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
|
|
PL4019041T3
(pl)
|
2012-07-13 |
2023-05-08 |
The Trustees Of The University Of Pennsylvania |
Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR
|
|
CN102775500A
(zh)
|
2012-08-03 |
2012-11-14 |
郑骏年 |
嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途
|
|
LT2884999T
(lt)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Ląstelinės imunoterapijos būdas ir kompozicijos
|
|
WO2014031476A1
(en)
|
2012-08-21 |
2014-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
US9879065B2
(en)
|
2012-09-14 |
2018-01-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors recognizing MHC class II-restricted MAGE-A3
|
|
US9416190B2
(en)
|
2012-09-27 |
2016-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
US9598489B2
(en)
|
2012-10-05 |
2017-03-21 |
The Trustees Of The Univeristy Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
|
WO2014059173A2
(en)
|
2012-10-10 |
2014-04-17 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
WO2014059248A1
(en)
|
2012-10-12 |
2014-04-17 |
Philadelphia Health & Education Corporation D/B/A/ Drexel |
Mir-155 enhancement of cd8+ t cell immunity
|
|
UY35103A
(es)
|
2012-10-29 |
2014-05-30 |
Glaxo Group Ltd |
Compuestos de cefem 2-sustituidos
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
SG11201505858VA
(en)
|
2013-01-28 |
2015-09-29 |
St Jude Childrens Res Hospital |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
IL305629A
(en)
|
2013-02-15 |
2023-11-01 |
Univ California |
Chimeric antigen receptor and methods of using it
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
WO2014130635A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
US9434935B2
(en)
|
2013-03-10 |
2016-09-06 |
Bellicum Pharmaceuticals, Inc. |
Modified caspase polypeptides and uses thereof
|
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
CA2905352A1
(en)
|
2013-03-14 |
2014-09-25 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling t cell proliferation
|
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
US9402888B2
(en)
|
2013-03-14 |
2016-08-02 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating cancer
|
|
US9561291B2
(en)
|
2013-03-15 |
2017-02-07 |
Imre Kovesdi |
Methods of targeting T-cells to tumors
|
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
|
US9393268B2
(en)
|
2013-03-15 |
2016-07-19 |
Thomas Jefferson University |
Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
|
EP2997134B1
(en)
|
2013-05-14 |
2020-06-24 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
EP2997146A4
(en)
|
2013-05-15 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
CA2913052A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
JP6608807B2
(ja)
|
2013-05-29 |
2019-11-20 |
セレクティス |
Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
|
|
EP3569253A1
(en)
|
2013-06-05 |
2019-11-20 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing partial apoptosis using caspase polypeptides
|
|
WO2014200891A1
(en)
|
2013-06-11 |
2014-12-18 |
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES |
Her2-specific monoclonal antibodies and conjugates thereof
|
|
US9243068B2
(en)
|
2013-06-25 |
2016-01-26 |
Vaccinex, Inc. |
Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases
|
|
CA3173052A1
(en)
|
2013-08-30 |
2015-03-05 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
|
EP3054987B1
(en)
|
2013-10-11 |
2019-10-09 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Tem8 antibodies and their use
|
|
AU2014337367B2
(en)
|
2013-10-15 |
2020-04-30 |
The Scripps Research Institute |
Peptidic chimeric antigen receptor T cell switches and uses thereof
|
|
AU2014337385B2
(en)
|
2013-10-15 |
2020-04-30 |
The Scripps Research Institute |
Chimeric antigen receptor T cell switches and uses thereof
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
EP3096742B1
(en)
|
2014-01-20 |
2024-06-12 |
University of Utah Research Foundation |
Compositions and methods for modifying the surface of cells and methods of use
|
|
US9694033B2
(en)
|
2014-01-24 |
2017-07-04 |
The Cleveland Clinic Foundation |
IL-9 secreting CD8+ Tc9 cells and methods of treating cancer
|
|
EP3104866A4
(en)
|
2014-02-14 |
2017-08-02 |
Bellicum Pharmaceuticals, Inc. |
Methods for activating t cells using an inducible chimeric polypeptide
|
|
CA2977839C
(en)
|
2014-02-28 |
2022-07-26 |
The Royal Institution For The Advancement Of Learning / Mcgill University |
Tc-ptp inhibitors as apc activators for immunotherapy
|
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
EP3114217A4
(en)
|
2014-03-07 |
2017-09-20 |
Bellicum Pharmaceuticals, Inc. |
Caspase polypeptides having modified activity and uses thereof
|
|
SG10202109752XA
(en)
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
US20170158749A1
(en)
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
US9885021B2
(en)
|
2014-06-12 |
2018-02-06 |
Children's National Medical Center |
Generation of broadly-specific, virus-immune cells targeting multiple HIV antigens for preventive and therapeutic use
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
BR112017000939A2
(pt)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico de cll-1
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
EP3177640B1
(en)
|
2014-08-08 |
2020-05-06 |
The Board of Trustees of the Leland Stanford Junior University |
High affinity pd-1 agents and methods of use
|
|
US11141494B2
(en)
|
2014-08-09 |
2021-10-12 |
Purdue Research Foundation |
Development of neurokinin-1 receptor-binding agent delivery conjugates
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
AU2015312117A1
(en)
|
2014-09-02 |
2017-03-02 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
|
|
ES2738705T3
(es)
|
2014-09-19 |
2020-01-24 |
Hope City |
Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
|
|
WO2016054520A2
(en)
|
2014-10-03 |
2016-04-07 |
The California Institute For Biomedical Research |
Engineered cell surface proteins and uses thereof
|
|
EP3206703B1
(en)
|
2014-10-14 |
2021-05-19 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Peptide for treating pancreatic cancer
|
|
MX2017006167A
(es)
|
2014-11-12 |
2018-03-23 |
Siamab Therapeutics Inc |
Compuestos que interactúan con glicanos y métodos de uso.
|
|
CN107708702A
(zh)
|
2014-11-17 |
2018-02-16 |
塞勒克塔生物科学有限公司 |
磷脂醚类似物作为靶向癌症的药物载体
|
|
EP3227317A4
(en)
|
2014-12-02 |
2018-04-25 |
Roger Williams Hospital |
Methods and compositons for treating cancer
|
|
WO2016100236A2
(en)
|
2014-12-15 |
2016-06-23 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
|
EP3234145B1
(en)
|
2014-12-15 |
2019-06-05 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled activation or elimination of therapeutic cells
|
|
WO2016098078A2
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Dimerization switches and uses thereof
|
|
HRP20240357T1
(hr)
|
2014-12-24 |
2024-06-07 |
Autolus Limited |
Stanica
|
|
US9765330B1
(en)
|
2015-01-09 |
2017-09-19 |
Nant Holdings Ip, Llc |
Compositions and methods for reduction of allograft recognition and rejection
|
|
EP3262166A4
(en)
|
2015-02-24 |
2018-08-15 |
The Regents of The University of California |
Binding-triggered transcriptional switches and methods of use thereof
|
|
BR112017018770A2
(pt)
|
2015-03-02 |
2018-04-17 |
Innovative Cellular Therapeutics CO., LTD. |
redução da tolerância imunológica induzida por pd-l1
|
|
CN107708710A
(zh)
|
2015-03-17 |
2018-02-16 |
嵌合体生物工程公司 |
Smart CAR装置,DE CAR多肽,Side CAR及其使用
|
|
WO2016149665A1
(en)
|
2015-03-18 |
2016-09-22 |
Baylor College Of Medicine |
Her2/erbb2 chimeric antigen receptor
|
|
US9717745B2
(en)
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
|
GB201505305D0
(en)
|
2015-03-27 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel Peptides and combination of peptides for use in immunotherapy against various tumors
|
|
WO2016168766A1
(en)
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized chimeric receptor t cell switches and uses thereof
|
|
CN107849102B
(zh)
|
2015-05-15 |
2022-05-13 |
希望之城 |
嵌合抗原受体组合物
|
|
US9636388B2
(en)
|
2015-05-19 |
2017-05-02 |
Morphogenesis, Inc. |
Multi-indication mRNA cancer immunotherapy
|
|
KR102349677B1
(ko)
|
2015-05-28 |
2022-01-12 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위해 환자를 컨디셔닝하는 방법
|
|
AU2016274989A1
(en)
|
2015-06-12 |
2017-11-02 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
|
US9663756B1
(en)
|
2016-02-25 |
2017-05-30 |
Flodesign Sonics, Inc. |
Acoustic separation of cellular supporting materials from cultured cells
|
|
CN107709356A
(zh)
*
|
2015-06-26 |
2018-02-16 |
南加利福尼亚大学 |
用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
|
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
|
US9790467B2
(en)
|
2015-09-22 |
2017-10-17 |
Qt Holdings Corp |
Methods and compositions for activation or expansion of T lymphocytes
|
|
ES2803728T3
(es)
|
2015-10-05 |
2021-01-29 |
Prec Biosciences Inc |
Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
|
|
GB201518817D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Cell
|
|
GB201518816D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Receptor
|
|
TWI724056B
(zh)
|
2015-11-19 |
2021-04-11 |
美商卡默森屈有限公司 |
Ｃｘｃｒ２抑制劑
|
|
TWI734715B
(zh)
|
2015-11-19 |
2021-08-01 |
美商卡默森屈有限公司 |
趨化因子受體調節劑
|
|
CA3007473A1
(en)
|
2015-12-14 |
2017-06-22 |
Bellicum Pharmaceuticals, Inc. |
Dual controls for therapeutic cell activation or elimination
|
|
US9849092B2
(en)
|
2015-12-21 |
2017-12-26 |
Gholam A. Peyman |
Early cancer detection and enhanced immunotherapy
|
|
MX2018008416A
(es)
|
2016-01-08 |
2019-11-11 |
Univ California |
Polipéptidos heterodímericos condicionalmente activos y métodos para su uso.
|
|
WO2017123559A2
(en)
|
2016-01-11 |
2017-07-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric proteins and methods of regulating gene expression
|
|
GB201602571D0
(en)
|
2016-02-12 |
2016-03-30 |
Autolus Ltd |
Signalling system
|
|
GB201602563D0
(en)
|
2016-02-12 |
2016-03-30 |
Autolus Ltd |
Signalling system
|
|
CN108697798A
(zh)
*
|
2016-02-16 |
2018-10-23 |
达纳-法伯癌症研究所有限公司 |
免疫疗法组合物及方法
|
|
CN108884460B
(zh)
|
2016-03-19 |
2023-04-28 |
埃克苏马生物技术公司 |
淋巴细胞转导及其扩增调节的方法与组合物
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
CN109476743A
(zh)
|
2016-03-22 |
2019-03-15 |
西雅图儿童医院(以西雅图儿童研究所名义营业) |
预防或缓解毒性的早期干预方法
|
|
CA3019835A1
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
GB201610515D0
(en)
|
2016-06-16 |
2016-08-03 |
Autolus Ltd |
Cell
|
|
GB201610512D0
(en)
|
2016-06-16 |
2016-08-03 |
Autolus Ltd |
Chimeric antigen receptor
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
AU2017295704B2
(en)
|
2016-07-13 |
2023-07-13 |
President And Fellows Of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
|
US9642906B2
(en)
|
2016-09-16 |
2017-05-09 |
Baylor College Of Medicine |
Generation of HPV-specific T-cells
|
|
US10617720B2
(en)
|
2016-10-20 |
2020-04-14 |
Miltenyi Biotech, GmbH |
Chimeric antigen receptor specific for tumor cells
|
|
WO2018111763A1
(en)
|
2016-12-12 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
CA3045667A1
(en)
|
2016-12-13 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
|
EP3336107A1
(en)
|
2016-12-15 |
2018-06-20 |
Miltenyi Biotec GmbH |
Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
|
|
JP7078937B2
(ja)
|
2016-12-21 |
2022-06-01 |
ダンマークス テクニスク ユニバーシテット |
免疫細胞を操作するための抗原提示足場
|
|
AU2018219226B2
(en)
*
|
2017-02-07 |
2024-12-19 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
ES3024357T3
(en)
|
2017-02-17 |
2025-06-04 |
Purdue Research Foundation |
Targeted ligand-payload based drug delivery for cell therapy
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
WO2019144095A1
(en)
*
|
2018-01-22 |
2019-07-25 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for car t cells
|
|
AU2019218729B2
(en)
*
|
2018-02-06 |
2025-12-04 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
|
|
KR20210074274A
(ko)
*
|
2018-08-06 |
2021-06-21 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
합텐 표지된 세포로의 키메라 항원 수용체 t 세포의 자극을 위한 방법 및 조성물
|
|
CA3140210A1
(en)
*
|
2019-03-13 |
2020-09-17 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Sodium fluorescein as a reversal agent for an anti-fluorescein car t cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers
|
|
AU2020309505A1
(en)
*
|
2019-07-05 |
2022-01-27 |
Purdue Research Foundation |
Design and efficient synthesis of lipid-fluorescein conjugates for CAR-T cell therapy
|
|
WO2021158534A1
(en)
*
|
2020-02-04 |
2021-08-12 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells
|